Global nutraceuticals company Royal DSM recently announced a partnership with cannabinoid ingredients and finished products manufacturer Mile High Labs (MHL) to create a platform in which leading consumer products companies can deliver novel, health-benefit driven products. DSM and MHL will also partner in the development of unique hemp-derived cannabinoid solutions.
 
DSM reports that with consumers increasingly turning to CBD for stress, mood, and sleep support, among other health benefits, CBD is set to disrupt the dietary supplements category, and market conditions present an opportunity for a platform that supports brands in achieving rapid, scalable CBD growth.
 
Enabled by MHL’s large-scale 400,000 square-foot manufacturing facilities, the partnership will see DSM apply its scientific, applications, and formulations expertise to combine CBD and hemp derivatives with high-quality micronutrients,. The resulting market-ready and premix solutions will enable dietary supplement, food, beverage, and other product brands to quickly deliver new products with speed and confidence, DSM reports.
 
“There is a strong consumer pull in the CBD space for high-quality, health-benefit driven solutions, but as yet the market is still to arrive at recognized science or quality standards. DSM has the core competencies, combined with a deep understanding of consumer and customer needs, to help brands enter the cannabinoid market early and build a leading position. Our science-backed solutions will deliver the purity, reliability, and traceability that are currently lacking and enable our customers to truly differentiate themselves,” Frederic Boned, vice president of Human Nutrition & Health at DSM North America, said.
 
“MHL is the ideal partner due to its staunch commitment to sustainability, quality, and regulatory compliance, as well as its extensive cannabinoid manufacturing capabilities. Together, we are committed to developing the standards the cannabinoid industry sorely needs. Our complementary areas of expertise will support customers along the entire product development process,” he continued.
 
“MHL is excited to team up with such a credible player in human nutrition and health, and one that so closely aligns with our ambitions to uncover the full potential of this space,” Jonathan Hilley, CEO of MHL, said. “This partnership is an important milestone in the evolution of MHL and a defining moment for our industry. We look forward to pooling our expertise to deliver cannabinoid innovation that is scalable, sustainable, cost-effective, and provides the building blocks for exciting new consumer products.”
 
DSM’s longer-term ambitions will be to leverage the company’s clinical, regulatory, and applications expertise to explore potential benefits of minor cannabinoids. DSM plans to partner closely with customers to develop the next generations of science-backed cannabinoid solutions.
 
“This is just the beginning for DSM. Our partnership with MHL will be a key enabler for us as we take our first steps in this burgeoning market,” Boned added. “The potential of CBD and other hemp-derived cannabinoids hasn’t yet been fully realized, so we’re investing in the future of the category. As regulatory frameworks are defined, DSM’s end-to-end capabilities and unrivalled portfolio make us ideally positioned to lead and shape the market. This category is full of promise, and we’re excited to partner with MHL and play an integral role in tapping into the potential and enabling customers to create products with real purpose. Watch this space!”